Frontiers in immunologyOct 17, 2026

How Gut Bacteria and Their Chemicals Affect Vaccine Response and Lasting Immunity Depending on the Situation

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 18, 2026

Abstract

Vaccine responses may be influenced by the intestinal microbiome, which has shown a connection to vaccine outcomes.

Vaccine response variability is linked to factors such as age, genetics, and prior antigen exposure, but these factors do not fully account for differences.
The intestinal microbiome may modulate vaccine responses through microbial metabolites and non-metabolic signals.
Short-chain fatty acids, particularly acetate, propionate, and butyrate, show varied effects on immune responses, but direct mediation in human vaccination is not yet established.
Null findings in specific studies suggest that a universal dependence on the microbiome for vaccine efficacy may not exist.
Microbiome-guided vaccination is still an ongoing area of research rather than a standard clinical approach.

Simplified

Vaccine responses vary markedly between individuals, yet age, genetics, prior antigen exposure, comorbidity, nutrition and vaccine platform explain only part of this heterogeneity. The intestinal microbiome is a candidate modulator through microbial metabolites and parallel non-metabolic signals. Human studies link microbial features to vaccine outcomes, but taxa rarely replicate across geography, age and platform. Small randomised antibiotic studies identify effects of treatment assignment, not necessarily microbiome mediation; infant microbial rescue has been demonstrated in mice rather than infants. Amongst the pathways considered, short-chain fatty acids have the largest mechanistic evidence base, predominantly preclinical, but acetate, propionate and butyrate differ in targets, exposure and direction of effect, and direct human vaccine mediation remains unestablished. Null findings for BNT162b2 in microbiota-depleted mice and for overall antibody responses in an older-adult probiotic trial argue against universal microbiome dependence or probiotic benefit. We organise the evidence around a microbial function-mediator-exposure-immune-checkpoint-endpoint chain, retaining a primary focus on metabolites. Vaccine take, peak antibody, decay and recall are distinguished from clinical protection. We also separate microbiome-modifying probiotics from antigen-delivery platforms. A decision-gated workflow links signature discovery, source and target verification, independent validation, randomised intervention and demonstrated clinical utility. Microbiome-guided vaccination remains a research strategy rather than an established clinical practice.

Full Text

Full text is available at the source.

View Full Text ↗

How Gut Bacteria and Their Chemicals Affect Vaccine Response and Lasting Immunity Depending on the Situation

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief